Ozpharm Limited - Period Ending 2019-08-31

Ozpharm Limited - Period Ending 2019-08-31


Ozpharm Limited 02299269 false 2018-09-01 2019-08-31 2019-08-31 The principal activity of the company is pharmacy Digita Accounts Production Advanced 6.24.8820.0 Software true false 02299269 2018-09-01 2019-08-31 02299269 2019-08-31 02299269 bus:OrdinaryShareClass1 2019-08-31 02299269 core:RetainedEarningsAccumulatedLosses 2019-08-31 02299269 core:ShareCapital 2019-08-31 02299269 core:CurrentFinancialInstruments 2019-08-31 02299269 core:CurrentFinancialInstruments core:WithinOneYear 2019-08-31 02299269 core:AdditionsToInvestments 2019-08-31 02299269 core:CostValuation 2019-08-31 02299269 core:DisposalsDecreaseInInvestments 2019-08-31 02299269 core:FurnitureFittingsToolsEquipment 2019-08-31 02299269 core:LandBuildings 2019-08-31 02299269 bus:SmallEntities 2018-09-01 2019-08-31 02299269 bus:AuditExemptWithAccountantsReport 2018-09-01 2019-08-31 02299269 bus:FullAccounts 2018-09-01 2019-08-31 02299269 bus:SmallCompaniesRegimeForAccounts 2018-09-01 2019-08-31 02299269 bus:RegisteredOffice 2018-09-01 2019-08-31 02299269 bus:CompanySecretaryDirector1 2018-09-01 2019-08-31 02299269 bus:Director2 2018-09-01 2019-08-31 02299269 bus:OrdinaryShareClass1 2018-09-01 2019-08-31 02299269 bus:PrivateLimitedCompanyLtd 2018-09-01 2019-08-31 02299269 core:FurnitureFittings 2018-09-01 2019-08-31 02299269 core:FurnitureFittingsToolsEquipment 2018-09-01 2019-08-31 02299269 core:LandBuildings 2018-09-01 2019-08-31 02299269 countries:England 2018-09-01 2019-08-31 02299269 2018-08-31 02299269 core:FurnitureFittingsToolsEquipment 2018-08-31 02299269 core:LandBuildings 2018-08-31 02299269 2017-09-01 2018-08-31 02299269 2018-08-31 02299269 bus:OrdinaryShareClass1 2018-08-31 02299269 core:RetainedEarningsAccumulatedLosses 2018-08-31 02299269 core:ShareCapital 2018-08-31 02299269 core:CurrentFinancialInstruments 2018-08-31 02299269 core:CurrentFinancialInstruments core:WithinOneYear 2018-08-31 02299269 core:FurnitureFittingsToolsEquipment 2018-08-31 02299269 core:LandBuildings 2018-08-31 iso4217:GBP xbrli:pure xbrli:shares

Registration number: 02299269

Ozpharm Limited

Annual Report and Unaudited Financial Statements

for the Year Ended 31 August 2019

Wall and Partners
Chartered Accountants
3 & 5 Commercial Gate
Mansfield
Nottinghamshire
NG18 1EJ


 

 

Ozpharm Limited

Contents

Company Information

1

Balance Sheet

2 to 3

Notes to the Unaudited Financial Statements

4 to 9

 

Ozpharm Limited

Company Information

Directors

Mr P Oza

Mrs P Oza

Company secretary

Mr P Oza

Registered office

50 Lowmoor Road
Kirkby in Ashfield
Nottingham
Nottinghamshire
NG17 7BG

Accountants

Wall and Partners
Chartered Accountants
3 & 5 Commercial Gate
Mansfield
Nottinghamshire
NG18 1EJ

 

Ozpharm Limited

(Registration number: 02299269 )
Balance Sheet as at 31 August 2019

Note

2019
£

2018
£

Fixed assets

 

Tangible assets

4

58,118

59,282

Investment property

5

-

1,322,129

 

58,118

1,381,411

Current assets

 

Stocks

7

69,000

61,800

Debtors

8

150,398

136,115

Cash at bank and in hand

 

4,684,739

4,428,795

 

4,904,137

4,626,710

Creditors: Amounts falling due within one year

9

(181,266)

(177,032)

Net current assets

 

4,722,871

4,449,678

Total assets less current liabilities

 

4,780,989

5,831,089

Provisions for liabilities

(3,187)

(2,936)

Net assets

 

4,777,802

5,828,153

Capital and reserves

 

Called up share capital

10

100

100

Profit and loss account

4,777,702

5,828,053

Total equity

 

4,777,802

5,828,153

For the financial year ending 31 August 2019 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006.

These financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime and the option not to file the Profit and Loss Account has been taken.

 

Ozpharm Limited

(Registration number: 02299269 )
Balance Sheet as at 31 August 2019

Approved and authorised by the Board on 29 May 2020 and signed on its behalf by:
 

.........................................

Mr P Oza
Company secretary and director

 

Ozpharm Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 August 2019

1

General information

The company is a private company limited by share capital, incorporated in England.

The address of its registered office is:
50 Lowmoor Road
Kirkby in Ashfield
Nottingham
Nottinghamshire
NG17 7BG

These financial statements were authorised for issue by the Board on 29 May 2020.

2

Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A - 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006.

Basis of preparation

These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

The Company's financial statements are presented in pounds sterling (£) which is also the Company's functional currency, and all values are rounded to the nearest pound.

Revenue recognition

Turnover comprises the fair value of the consideration received or receivable for the sale of goods and provision of services in the ordinary course of the company’s activities. Turnover is shown net of sales/value added tax, returns, rebates and discounts.

Foreign currency transactions and balances

Transactions in foreign currencies are initially recorded at the functional currency rate prevailing at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are retranslated into the respective functional currency of the entity at the rates prevailing on the reporting period date. Non-monetary items carried at fair value that are denominated in foreign currencies are retranslated at the rates prevailing on the initial transaction dates.

Non-monetary items measured in terms of historical cost in a foreign currency are not translated.

Tax

The tax expense for the period comprises current and deferred tax. Tax is recognised in profit or loss, except that a charge attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

 

Ozpharm Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 August 2019

The current corporation tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

Deferred tax is recognised in respect of all timing differences between taxable profits and profits reported in the financial statements.

Unrelieved tax losses and other deferred tax assets are recognised when it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference.

Tangible assets

Tangible assets are stated in the statement of financial position at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

Depreciation

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Asset class

Depreciation method and rate

Improvements to property

5% straight line

Fixture and fittings

15% reducing balance

Investment property

Investment property is carried at fair value, derived from the current market prices for comparable real estate determined annually by external valuers. The valuers use observable market prices, adjusted if necessary for any difference in the nature, location or condition of the specific asset. Changes in fair value are recognised in profit or loss.

Business combinations

Business combinations are accounted for using the purchase method. The consideration for each acquisition is measured at the aggregate of the fair values at acquisition date of assets given, liabilities incurred or assumed, and equity instruments issued by the group in exchange for control of the acquired, plus any costs directly attributable to the business combination. When a business combination agreement provides for an adjustment to the cost of the combination contingent on future events, the group includes the estimated amount of that adjustment in the cost of the combination at the acquisition date if the adjustment is probable and can be measured reliably.

Investments

Investments in equity shares which are publicly traded or where the fair value can be measured reliably are initially measured at fair value, with changes in fair value recognised in profit or loss. Investments in equity shares which are not publicly traded and where fair value cannot be measured reliably are measured at cost less impairment.


Interest income on debt securities, where applicable, is recognised in income using the effective interest method. Dividends on equity securities are recognised in income when receivable.

 

Ozpharm Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 August 2019

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Trade debtors

Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business.

Trade debtors are recognised initially at the transaction price. They are subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for the impairment of trade debtors is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of the receivables.

Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost is determined using the first-in, first-out (FIFO) method.

The cost of finished goods and work in progress comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the inventories to their present location and condition. At each reporting date, stocks are assessed for impairment. If stocks are impaired, the carrying amount is reduced to its selling price less costs to complete and sell; the impairment loss is recognised immediately in profit or loss.

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

Trade creditors are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.

Borrowings

Interest-bearing borrowings are initially recorded at fair value, net of transaction costs. Interest-bearing borrowings are subsequently carried at amortised cost, with the difference between the proceeds, net of transaction costs, and the amount due on redemption being recognised as a charge to the Profit and Loss Account over the period of the relevant borrowing.

Interest expense is recognised on the basis of the effective interest method and is included in interest payable and similar charges.

Borrowings are classified as current liabilities unless the company has an unconditional right to defer settlement of the liability for at least twelve months after the reporting date.

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

 

Ozpharm Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 August 2019

Dividends

Dividend distribution to the company’s shareholders is recognised as a liability in the financial statements in the reporting period in which the dividends are declared.

Defined contribution pension obligation

A defined contribution plan is a pension plan under which fixed contributions are paid into a pension fund and the company has no legal or constructive obligation to pay further contributions even if the fund does not hold sufficient assets to pay all employees the benefits relating to employee service in the current and prior periods.

Contributions to defined contribution plans are recognised as employee benefit expense when they are due. If contribution payments exceed the contribution due for service, the excess is recognised as a prepayment.

3

Staff numbers

The average number of persons employed by the company (including directors) during the year, was 10 (2018 - 10).

4

Tangible assets

Improvements to property
£

Fixtures and fittings
£

Total
£

Cost or valuation

At 1 September 2018

60,874

61,787

122,661

Additions

-

3,833

3,833

At 31 August 2019

60,874

65,620

126,494

Depreciation

At 1 September 2018

17,044

46,335

63,379

Charge for the year

2,486

2,511

4,997

At 31 August 2019

19,530

48,846

68,376

Carrying amount

At 31 August 2019

41,344

16,774

58,118

At 31 August 2018

43,830

15,452

59,282

Included within the net book value of land and buildings above is £41,344 (2018 - £43,830) in respect of freehold land and buildings.
 

5

Investment properties

 

Ozpharm Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 August 2019

2019
£

At 1 September

1,322,129

Disposals

(1,322,129)

At 31 August

-

6

Investments

Subsidiaries

£

Cost or valuation

Additions

1,390,001

Disposals

(1,390,001)

At 31 August 2019

-

Provision

Carrying amount

At 31 August 2019

-

A distribution of 1,390.001 shares in the company's subsidiary were distributed in specie in accordance with a group reconstruction.

7

Stocks

2019
£

2018
£

Other inventories

69,000

61,800

8

Debtors

2019
£

2018
£

Trade debtors

120,647

107,824

Prepayments

6,464

8,204

Other debtors

23,287

20,087

150,398

136,115

 

Ozpharm Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 August 2019

9

Creditors

Creditors: amounts falling due within one year

2019
£

2018
£

Due within one year

Trade creditors

96,842

98,940

Accruals and deferred income

11,010

3,381

Other creditors

73,414

74,711

181,266

177,032

10

Share capital

Allotted, called up and fully paid shares

 

2019

2018

 

No.

£

No.

£

Ordinary of £1 each

100

100

100

100